Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Sabine M.J. Welten
  • Rob C.M. de Jong
  • Anouk Wezel
  • Margreet R. de Vries
  • Martin C. Boonstra
  • Laura Parma
  • J. Wouter Jukema
  • Tetje C. van der Sluis
  • Ramon Arens
  • Ilze Bot
  • Sudhir Agrawal
  • Paul H.A. Quax
  • Nossent, Anne Yaël

Background and aims We aimed at investigating the role of 14q32 microRNAs in intimal hyperplasia and accelerated atherosclerosis; two major contributors to restenosis. Restenosis occurs regularly in patients treated for coronary artery disease and peripheral arterial disease. We have previously shown that inhibition of 14q32 microRNAs leads to increased post-ischemic neovascularization, and microRNA miR-494 also decreased atherosclerosis, while increasing plaque stability. We hypothesized that 14q32 microRNA inhibition has beneficial effects on intimal hyperplasia, as well as accelerated atherosclerosis. Methods Non-constrictive cuffs were placed around both femoral arteries of C57BL/6J mice to induce intimal hyperplasia. Accelerated atherosclerotic plaque formation was induced in hypercholesterolemic ApoE−/− mice by placing semi-constrictive collars around both carotid arteries. 14q32 microRNAs miR-329, miR-494 and miR-495 were inhibited in vivo using Gene Silencing Oligonucleotides (GSOs). Results GSO-495 administration led to a 32% reduction of intimal hyperplasia. Moreover, the number of macrophages in the arterial wall of mice treated with GSO-495 was reduced by 55%. Inhibition of miR-329 and miR-494 had less profound effects on intimal hyperplasia. GSO-495 administration also decreased atherosclerotic plaque formation by 52% and plaques of GSO-495 treated animals showed a more stable phenotype. Finally, cholesterol levels were also decreased in GSO-495 treated animals, via reduction of the VLDL-fraction. Conclusions GSO-495 administration decreased our primary outcomes, namely intimal hyperplasia, and accelerated atherosclerosis. GSO-495 administration also favourably affected multiple secondary outcomes, including macrophage influx, plaque stability and total plasma cholesterol levels. We conclude that 14q32 microRNA miR-495 is a promising target for prevention of restenosis.

OriginalsprogEngelsk
TidsskriftAtherosclerosis
Vol/bind261
Sider (fra-til)26-36
Antal sider11
ISSN0021-9150
DOI
StatusUdgivet - 1 jun. 2017

Bibliografisk note

Funding Information:
This work was supported by the Netherlands Institute for Regenerative Medicine (NIRM, FES0908), the Netherlands Organisation for Scientific Research (NWO, Veni-916.12.041) and the Dutch Heart Foundation (2010B029 and Dr. E. Dekker Senior Postdoc, 2014T102). We acknowledge the support from the Netherlands CardioVascular Research Initiative: “the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences” for the GENIUS project “Generating the best evidence-based pharmaceutical targets for atherosclerosis” (CVON2011-19).

Publisher Copyright:
© 2017 Elsevier B.V.

ID: 395076749